Browse > Article

Modulation of Immune Response Induced by Co-Administration of DNA Vaccine Encoding HBV Surface Antigen and HCV Envelope Antigen in BALB/c Mice  

Nam, Sang-Hyun (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
Park, Jae-Hyun (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
Kang, Ju-Hye (Biologics Evaluation Department, KFDA)
Kang, Seog-Youn (Biologics Evaluation Department, KFDA)
Kim, Jae-Hong (Inflammatory Signaling Laboratory, Graduate School of Biotechnology, Korea University)
Kim, So-Young (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
Ahn, Joon-Ik (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
Park, Ki-Sook (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
Chung, Hye-Joo (Department of Pharmacology, National Institute of Toxicological Research, KFDA)
Publication Information
Archives of Pharmacal Research / v.29, no.11, 2006 , pp. 1042-1048 More about this Journal
Abstract
Plasmid DNA vaccines encoding the hepatitis B virus (HBV) surface and hepatitis C virus (HCV) envelope antigens, respectively, were constructed, and attempt were made to find the possibility of a divalent vaccine against HBV and HCV. The expression of each plasmid in Cos-1 cells was confirmed using immunocytochemistry. To measure the induced immune response by these plasmids in vivo, female BALB/c mice were immunized intramuscularly with $100\;{\mu}g$ of either both or just one of the plasmids. Anti-HBV and HCV-specific antibodies and related cytokines were evaluated to investigate the generation of both humoral and cellular immune responses. As a result, specific anti-HBV and anti-HCV serum antibodies from mice immunized with these plasmids were observed using immunoblot. The levels of IL-2 and RANTES showing a $Th_{1}$ immune response were significantly increased, but there was no change in the level of IL-4 ($Th_{1}$ immune response) in any of the immunized groups. Compared with each plasmid DNA vaccine, the combined vaccine elicited similar immune responses in both humoral and cell-mediated immunities. These results suggest that the combined DNA vaccine can induce not only comparable immunity experimentally without antigenic interference, but also humoral and $Th_{1}$ dominant cellular immune responses. Therefore, they could serve as candidates for a simultaneous bivalent vaccine against HBV and HCV infections.
Keywords
DNA vaccine; HCV; HBV; IL-2; IL-4; RANTES;
Citations & Related Records

Times Cited By Web Of Science : 2  (Related Records In Web of Science)
Times Cited By SCOPUS : 1
연도 인용수 순위
1 Geissler, M., Tokushige, K., Wakita, T., Zurawski, V. R. Jr., and Wands, J. R., Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine, 16, 857-867 (1998)   DOI   ScienceOn
2 Hourvitz, A., Mosseri, R., Solomon, A., Yehezkelli, Y., Atsmon, J., and Danon, Y. L., Koren, R., and Shouval, D., Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J. Viral. Hepat., 3, 37-42 (1996)   DOI   ScienceOn
3 Romagnani, S., T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol., 85, 9-18 (2000)   DOI
4 Tedeschi, V., Akatsuka, T., Shih, J. W., Battegay, M., and Feinstone, S. M., A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2. Hepatology, 25, 459- 462 (1997)   DOI
5 Yang, J. S., Kim, J. J., Hwang, D., Choo, A. Y., Dang, K., Maguire, H., Kudchodkar. S., Ramanathan, M. P., and Weiner, D. B., Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNVNY1999). J. Infect. Dis., 184, 809-816 (2001)   DOI   ScienceOn
6 Decker, M. D., Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr. Infect. Dis. J., 20(Suppl), S10-8 (2001)   DOI   ScienceOn
7 Song, H. K., Noorchashm, H., Lin, T. H., Moore, D. J., Greeley, S. A., Caton, A. J., and Naji, A., Specialized CC-chemokine secretion by Th1 cells in destructive autoimmune myocarditis. J. Autoimmune, 21, 295-303 (2003)   DOI   ScienceOn
8 Jin, J., Yang, J. Y., Liu, J., Kong, Y. Y., Wang, Y., and Li, G. D., DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune reponses to both HCV and HBV. World J. Gastroenterol., 8, 505-510 (2002)   DOI
9 Yap. I., Guan, R., and Chan, S. H ., Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein preliminary study on immunogenicity. Vaccine, 10, 439-442 (1992)   DOI   ScienceOn
10 Beckebaum, S., Cicinnati, V. T., and Gerken, G., DNA-based immunotherapy: potential for treatment of chronic viral hepatitis? Rev. Med. Virol., 12, 297-319 (2002)   DOI   ScienceOn
11 Pinto, A. R., Reyes-Sandoval, A., and Ertl, H. C., Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell. Immunol., 224,106-113 (2003)   DOI   ScienceOn
12 Ljungberg, K., Rollman, E., Eriksson, L., Hinkula, J., and Wahren, B., Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology, 302, 44-57 (2002)   DOI   ScienceOn
13 Nakano, I., Maertens, G., Major, M. E., Vitvitski, L., Dubisson, J., Fournillier, A., Martyroff, G. D., Trepo, C., and Inchauspe. G., Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J. Virol., 71, 7101-7109 (1997)
14 Suh, D. J. and Jeong, S. H., Current status of hepatitis C virus infection in Korea. Intervirology, 49, 70-75 (2006)   DOI   ScienceOn
15 Krahn, M. D., John-Baptiste A., Yi, Q., Doria, A., Remis, R. S., Ritvo, P. and Friedman, S., Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine, 23, 1549-1558 (2005)   DOI   ScienceOn
16 Fried M. W. and Hoofnagle J. H., Therapy of hepatitis C. Semin. Liver. Dis., 15, 82-91 (1995)   DOI   ScienceOn
17 Musacchio, A., Rodriguez, E. G., Herrera, A. M., Quintana, D., and Muzio, V., Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens. Biochem. Biophys. Res. Commun., 282, 442-446 (2001)   DOI   ScienceOn
18 Major, M. E., Vitvitski, L., Mink, M. A., Schleef, M., Whalen, R. G., Trepo, C., and Inchauspe, G., DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol., 69, 5798–5805 (1995)
19 Wright, T. L. and Lau, J. Y., Clinical aspects of hepatitis B virus infection. Lancet, 324, 1340-1344 (1993)
20 Liu, M., Acres, B., Balloul, J. M., Bizouarne, N., Paulm S., Slos, P., and Squiban, P., Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. U.S.A., 101, 14567- 14571 (2004)
21 Lagging, L. M., Meyer, K., Hoft, D., Houghton, M., Belshe, R. B., and Ray, R., Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J. Virol., 69, 5859-5863 (1995)